Bristol-Myers Squibb Company
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000DQLV23
BMY
Bristol-Myers Squibb Company
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Drug Manufacturers—General
NAME
Bristol-Myers Squibb Company
ISIN
US1101221083
TICKER
BMY
MIC
XNYS
REUTERS
BMY.N
BLOOMBERG
BMY US
F&G:
75
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Fr., 27.06.2025
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR T cell therapies, Breyanzi® (lisocabtagene maraleucel; liso-cel) for the treatment of large B cell lymphoma (LBCL) and other lymphomas and Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of mu...
Bristol-Myers Squibb
Di., 17.06.2025
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on August 1, 2025, to stockholders of record at the close of business on July 3, 2025.
In addition, the Board of Directors ...
Bristol-Myers Squibb
Mo., 16.06.2025
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb (NYSE: BMY) today announced the first disclosure of the primary analysis results of the marginal zone lymphoma (MZL) cohort of TRANSCEND FL, an open-label, global, multicenter, Phase 2, single-arm study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory disease. The new data will b...
Bristol-Myers Squibb
Do., 12.06.2025
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of new data from its targeted protein degradation platform during the 2025 European Hematology Association (EHA) Annual Congress being held from June 12-15 in Milan, Italy. Presentations feature updated clinical findings on the company’s investigational oral CELMoD™ agents mezigdomi...
Bristol-Myers Squibb
Do., 12.06.2025
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2025 on Thursday, July 31, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET.
Investors and the general public are invited to listen to a live webcast of the call at http://investo...
Bristol-Myers Squibb
Mi., 11.06.2025
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb (NYSE:BMY) today announced positive data from the pivotal Phase 3 POETYK PsA-1 trial (IM011-054) evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) who were not previously treated with a biologic disease-modifying antirheumatic drug (bDMARD). The trial met its primar...
Bristol-Myers Squibb
Mo., 02.06.2025
Bristol-Myers Squibb
US1101221083
BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work joint...
Bristol-Myers Squibb
Mi., 28.05.2025
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025.
The company will take part in a fireside chat beginning at 10:00 a.m. ET.
Investors and the general public are invited to listen to the session by visiting http://investor...
Bristol-Myers Squibb
Mi., 28.05.2025
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved a new Opdivo® (nivolumab) formulation associated with a new route of administration (subcutaneous use [SC]), a new pharmaceutical form (solution for injection) and a new strength (600 mg/vial). Opdivo SC, or nivolumab for subcutaneous use co-formulated ...
Bristol-Myers Squibb
Do., 22.05.2025
Bristol-Myers Squibb
US1101221083
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting to be held May 30-June 3 in Chicago, Illinois. Data from more than 80 company-sponsored studies, investigator-sponsored studies, and collaborations showcase re...
Bristol-Myers Squibb
Informationen zu Product Placements
BARRISTA SMART * AD
P R O D U C T S U G G E S T I O N S
